Abstract：
Cancer-associated thrombosis (CAT) is an important prognostic factor for an increasing number of cancer patients. Understanding of CAT among cancer care providers has grown in recent years, and guidelines for the prevention and treatment of CAT have been published in Japan and around the world. In this article, we introduce these major guidelines and discuss differences we identified between the Japanese guidelines and those of other countries, with a focus on problems and issues. Insurance coverage of low-molecular-weight heparin and indications for primary prevention with direct oral anticoagulants in particular require urgent consideration.
摘要：
癌症相关血栓形成（CAT）是越来越多的癌症患者的重要预后因素。近年来，癌症护理提供者对CAT的了解有所增加，以及预防和治疗CAT的指南已在日本和世界各地发布。在这篇文章中,我们介绍这些主要准则，并讨论我们发现的日本准则与其他国家的准则之间的差异，专注于问题和问题。低分子量肝素的保险范围和直接口服抗凝剂的一级预防适应症尤其需要紧急考虑。
